PDCD1 and neoplasm: To better understand the association between metabolic alterations and ICB responses, we performed untargeted metabolomics of plasma samples from B16-F0 tumour-bearing mice with vehicle or ICB (anti-PD1 plus anti-CTLA4) treatment (Supplementary Fig. 1a).